Onyx Therapeutics, Inc. v. CIPLA Limited

CourtDistrict Court, D. Delaware
DecidedFebruary 17, 2023
Docket1:16-cv-00988
StatusUnknown

This text of Onyx Therapeutics, Inc. v. CIPLA Limited (Onyx Therapeutics, Inc. v. CIPLA Limited) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Onyx Therapeutics, Inc. v. CIPLA Limited, (D. Del. 2023).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ONYX THERAPEUTICS, Inc., Plaintiff, V. Civil Action No. 16-988-GBW CIPLA Ltd. & CIPLA USA Inc., Defendants.

MEMORANDUM ORDER Plaintiffs Onyx Therapeutics, Inc. (“Onyx”) sued Defendants Cipla Ltd. and Cipla USA, Inc. (collectively, “Cipla”) for infringement of multiple patents. D.I. 1 § 7. Fifteen additional Defendants were at various points part of the case, but three Defendants settled with Onyx in February 2018, see C.A. No. 15-988, Order of Feb. 7, 2018; Order of Feb. 14, 2018, and the Court entered consent judgments as to 12 additional defendants in May 2019, D.I. 504; D.I. 505; D.I. 506; D.I. 507; D.I. 508; D.I. 509; D.I. 513; D.I. 514. A bench trial was held on May 6-16, 2019, D.I. 523; D.I. 529, and the Court found valid and infringed four claims across three patents-in-suit, D.I. 549. The Federal Circuit upheld the judgment. D.I. 553. Onyx moved for taxation of costs from the Clerk of Court (the “Clerk”), D.I. 557, and the Clerk granted-in-part and denied-in-part Onyx’s motion, D.I. 564. Pending now before the Court is Onyx’s Motion for Review of Taxation of Costs (the “Motion,” D.I. 565). The Court has reviewed the parties’ briefing, D.I. 566; D.I. 578; D.I. 581, and no hearing is necessary. For the reasons below, the Court grants-in-part and denies-in-part the Motion and taxes Cipla $48,146.36 in costs in favor of Onyx. I. BACKGROUND Trial began on May 6, 2019. Defendants Fresenius Kabi USA LLC and Fresenius Kabi USA Inc. (“Fresenius”), InnoPharma Inc. (“InnoPharma”), Apotex Inc. and Apotex Corp.

(“Apotex”), Sagent Pharmaceuticals, Inc. (“Sagent”), and Aurobindo Pharma USA Inc. (“Aurobindo”) reached proposed consent judgments on the eve of trial, D.I. 504; D.I. 505; D.L 506; D.I. 507 D.I. 508, while Qilu Pharma, Inc. and Qilu Pharmaceutical Co., Ltd. (“Quilu”) and Teva Pharmaceuticals USA, Inc. (“Teva”) had settled in February 2018, D.I. 114; D.I. 132. Thus, trial proceeded only against Defendants Cipla, Breckenridge Pharmaceutical Inc. (“Breckenridge”), MSN Pharmaceuticals Inc. and MSN Laboratories Private Ltd. (“MSN”), and Dr. Reddy’s Laboratories Inc. and Dr. Reddy’s Laboratories Ltd. (“Dr. Reddy’s”). D.I. 523 at 6:19-7:7. Proposed consent judgments were submitted as to MSN on May 7, 2019, D.I. 503, as to Dr. Reddy’s on May 9, 2019, D.I. 510, and as to Breckenridge on May 10, 2019, D.I. 511. Thus, the Court only entered final judgment as to Cipla on May 13, 2020, following post-trial briefing. D.I. 549. After appeal of this case concluded on April 30, 2021, D.I. 554, Onyx filed its Bill of Costs with the Clerk on May 14, 2021, D.I. 557. Cipla filed objections two weeks later. D.I. 561. Onyx sought the following costs: (A) $775 in clerk fees; (B) $9,300.43 for pretrial and trial transcripts; (C) $44,282.03 for deposition transcript costs; (D) $13,793.81 for witness traveling costs, lodging, and fees; (E) copying and exemplification costs, including $242,051.44 in document production costs, $45,236.16 in document copying costs for trial, and $308,193.98 in demonstrative and presentation costs for trial; and (F) $11,346.75 in costs for “certified file wrappers of the patents in suit[.]” D.I. 557 at passim. Cipla took issue with certain cost categories and with assessment of all charges against only one Defendant, Cipla. See D.I. 561. The clerk granted-in-part Onyx’s fee request. D.I. 564. The clerk granted $775 for “Fees of the Clerk,” $6,765.63 for “Fees for Witnesses,” and $945.00 for fees for obtaining copies of the patent file wrappers. D.I. 564 at 11. The Clerk denied all other costs. Jd. Onyx then brought the present Motion. D.I. 565.

II. LEGAL STANDARD Under Delaware Local Rule 54.1, “the prevailing party shall be entitled to costs.” D. Del. LR 54.1(a)(1); see Fed. R. Civ. P. 54(d)(1). “Costs [are] taxed in conformity with the provisions of 28 U.S.C. §§ 1920, 1921, and 1923,” among others, “and the remaining paragraphs .. . of this Rule.” D. Del. LR 54.1(6)(1). The Local Rule provides for taxation of transcript fees, deposition costs, witness fees, mileage, and subsistence, and costs of copying papers, among others. I/d. 54.1(b). Statute similarly provides that [a] judge or clerk . . . may tax as costs . . . (1) [flees of the clerk and marshal; (2) [flees for printed or electronically recorded transcripts necessarily obtained for use in the case; (3) [f]ees and disbursements for printing and witnesses; (4) [flees for exemplification and the costs of making copies of any materials where the copies are necessarily obtained for use in the case; (5) Docket fees . . . ; [and] (6) Compensation of court appointed experts[] . . . [and] interpreters... .” 28 U.S.C. § 1920. Costs are limited “to those enumerated in 28 U.S.C. § 1920.” Reger v. The Nemours Found., Inc., 599 F.3d 285, 288 (3d Cir. 2010). The Supreme Court “has accorded a narrow reading of” § 1920. Race Tires Am., Inc. v. Hoosier Racing Tire Corp., 674 F.3d 158, 171 (3d Cir. 2012); see Taniguchi v. Kan Pac. Saipan, Ltd., 566 U.S. 560, 573 (2012) (describing the “narrow scope of taxable costs). Thus, fees are available for making copies, but “only scanning and file format conversion can be considered to be making copies.” Camesi v. Univ. of Pittsburgh Med. Ctr., 753 F. App’x 135, 139 (3d Cir. 2018) (internal quotation marks and citation omitted). The Third Circuit has explained that [a] district court’s review of the clerk’s determination of costs is de novo. However, there is a “strong presumption” that costs are to be awarded to the prevailing party. “Only if the losing party can introduce evidence, and the district court can articulate reasons within the bounds of its equitable power, should costs be reduced... .” Thus, if a district court, within its discretion, denies or reduces a prevailing party’s award of costs, it must articulate its reasons for doing so.

Reger, 599 F.3d at 288 (citations and footnote omitted); see Carroll v. Clifford Twp., 625 F. App’x 43, 47 (3d Cir. 2015) (quoting Reger, 599 F.3d at 288). The Third Circuit has also explained that, while a district Court may consider “the prevailing party’s unclean hands, bad faith, dilatory tactics, or failures to comply with process” and “the losing parties’ . . . inability to pay[,]” the Court may not consider the merits of the decision to pursue litigation, the “closeness of the issues[,]” or disparities in wealth between the parties. Reger, 599 F.3d at 288 n.3 (citations omitted). III. DISCUSSION The parties do not dispute that Onyx prevailed in this case. D.I. 566 at 3; D.I. 578 at 2. Onyx seeks $657,549.67 in costs, D.I. 566 at 1, while Cipla asks the Court to “affirm the Clerk’s Taxation of Costs[,]” or $8,485.63, D.I. 578 at 1-2 & n.1. The parties dispute both which costs are allowable and whether the Court should apportion those costs and, thus, charge Cipla only a fraction of the allowable costs that Onyx incurred. For the reasons below, the Court taxes $48,146.36 in favor of Onyx and against Cipla. a. Allowable Costs The parties do not contest that the costs the Clerk taxed against Cipla are allowable.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Taniguchi v. Kan Pacific Saipan, Ltd.
132 S. Ct. 1997 (Supreme Court, 2012)
Reger v. THE NEMOURS FOUNDATION, INC.
599 F.3d 285 (Third Circuit, 2010)
Donald Carroll v. Clifford Township
625 F. App'x 43 (Third Circuit, 2015)

Cite This Page — Counsel Stack

Bluebook (online)
Onyx Therapeutics, Inc. v. CIPLA Limited, Counsel Stack Legal Research, https://law.counselstack.com/opinion/onyx-therapeutics-inc-v-cipla-limited-ded-2023.